Rate My Professor Vandana Abramson

Abramson's research specializes in breast cancer, focusing on mechanisms of treatment response and resistance, as well as phase I/II clinical trials of novel combination therapies. Her influential publications include 'Subtyping of triple-negative breast cancer: implications for therapy' (Cancer, 2015), 'A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67' (Clinical Cancer Research, 2017), 'Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors' (Clinical Cancer Research, 2017), 'A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer' (Clinical Cancer Research, 2017), and 'Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations' (Journal of Clinical Oncology, 2016). She has authored over 200 research works with more than 10,000 citations. Abramson received the Conquer Cancer Foundation's Advanced Clinical Research Award in Breast Cancer. Her leadership and contributions have advanced understanding and treatment strategies in breast oncology.